Clinical Trial Update: Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension [Phase 3]

View source ↗

Summary

Phase 3 trial update for telmisartan/HCTZ combination therapies in hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Telmisartan/HCTZ 40 mg/12.5 mg (telmisartan/hydrochlorothiazide)
• Telmisartan/HCTZ 80 mg/12.5 mg (telmisartan/hydrochlorothiazide)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hypertension | Phase 3 | Status: COMPLETED